Aarti Drugs reported 7.1% rise in consolidated net profit to Rs 55.34 crore in Q4 FY22 from Rs 51.65 crore posted in Q4 FY21.
The company's consolidated net sales jumped 38.4% to Rs 694.27 crore in Q4 FY22 compared to Rs 501.75 in Q4 FY21. Profit before tax rose 8% year on year to Rs 70.5 crore in Q4 FY22.Total expenses were up by 43.2% year on year to Rs 626.73 crore in Q4 FY22. Cost of raw materials consumed stood at Rs 471.08 crore, rising by 56.3% year on year in the quarter ended 31 March 2022.
On full year basis, the pharma company posted a 26.9% decline in net profit to Rs 205.04 crore despite a 15.5% increase in net sales to Rs 2,488.65 crore in FY22 over FY21.
Aarti Drugs is primarily involved in manufacturing and marketing of active pharmaceutical ingredients (API), pharma intermediates and specialty chemicals.
Shares of Aarti Drugs closed 0.15% lower to end at Rs 445 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app